U.S. & Europe Atopic Dermatitis Market Size:
Atopic dermatitis or atopic eczema is a common, relapsing, chronic, and an inflammatory disease characterized by itchy skin and lesions. Atopic dermatitis primarily effects in infants, children, and also rarely effects in the adult population. Atopic dermatitis is associated with inhalant allergies (such as hay fever), asthma, and chronic dermatitis. In atopic dermatitis condition, the skin becomes inflamed and extremely itchy, that causes cracking, redness, weeping, vesicle formation, swelling, scaling, and crushing. The common risk factors for atopic dermatitis are inhalant allergens, food allergens, exposure to harsh soaps and detergents, and cold weather, and sometimes it causes due to genetics or heritability. People living in dry climate are more likely to get affected with atopic dermatitis.
U.S. and Europe Atopic Dermatitis Market Outlook:
The U.S. and Europe atopic dermatitis market is growing at a significant CAGR due to change in lifestyle, increase in atopic dermatitis population, and pollution and climatic changes. Growing prevalence of the food allergies and growing focus on new therapies are the key factors drive the U.S. and Europe atopic dermatitis market growth. Furthermore, increase in use of pharmacological products in developed countries. Increase in R&D expenditure to develop novel biologics, and improvement in healthcare expenditure might increase the growth of U.S. and Europe atopic dermatitis market over the forecast period. However, the challenge is time to be taken in drug adoption, high price and legal regulations might hamper the growth of U.S. and Europe atopic dermatitis market. Similarly, highly generalized nature of the atopic dermatitis market and lack of awareness on drug usage hinder the growth of U.S. and Europe atopic dermatitis market over the forecast period.
The U.S. and Europe atopic dermatitis market is segmented on the basis of drug class, route of administration, and distribution channel
Based on drug class, U.S. and Europe atopic dermatitis market segmented into the following:
- PDE-4 Inhibitor
- Biologic Therapy
- Calcineurin Inhibitors
Based on the route of administration,
Based on distribution channel,
- Hospital pharmacies
- Online pharmacies
- Drug stores
- Retail pharmacies
Various companies in atopic dermatitis market are focussed on partnerships with other companies to develop products. For instance, in October 2016, Allergan plc, successfully completed purchasing all outstanding shares of Vitae Pharmaceuticals, Inc., focussed on innovative development programs for dermatologic conditions. The completion of the Vitae acquisition added highly differentiated development compounds to Allergan’s medical dermatology pipeline. Furthermore, acquisitions take place in the atopic dermatitis space are accelerating the growth of the atopic dermatitis market. In July 2016, Leo Pharma acquired global license from AstraZeneca for monoclonal antibody tralokinumab that completed clinical phase 2b. In December 2016, Novartis acquired Ziarco Group Limited including ZPL389, an oral drug used in the treatment of atopic dermatitis. Launch of new products, new product approvals from U.S. and Europe regulatory bodies might increase the growth of U.S. and Europe atopic dermatitis market. For instance, in December 2016, The FDA approved Eucrisa (Crisaborole) ointment manufactured by Pfizer used in the treatment of mild to moderate eczema (atopic dermatitis) in patients with two years of age. The launch of new classes of drugs gives patients and healthcare professional’s alternatives to other classes of drugs such as corticosteroids, and calcineurin inhibitors.
U.S. and Europe hold a dominant share in the global atopic dermatitis market. U.S. accounts for largest share followed by Europe. U.S. market growing at significant rate due to increase in the prevalence of atopic dermatitis (According to the National Eczema Association (NEA), atopic dermatitis affects nearly 10% to 20% of infants in the U.S.). Newer drug approvals, increase in healthcare expenditure, and revised reimbursement policies might increase the growth of atopic dermatitis market in U.S. Europe holds the second largest share in global atopic dermatitis market due to change in lifestyle, food habituations, development in research and drug development, and the development of healthcare infrastructure. The increase in the prevalence of allergic conditions (According to Allergo Journal International, 40.8 % of German adolescents and children were sensitized to a minimum of one food allergens or inhalants measured) in European region also increases the growth of Europe atopic dermatitis market.
Some of the players in U.S. and Europe atopic dermatitis market are Sanofi (France), Galderma SA (Nestle) (Switzerland), Allergan (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.), Bayer AG (Germany), Otsuka Pharmaceutical Co., Ltd (Japan), Regeneron Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Encore Dermatology, Inc. (U.S.), Medimetriks Pharmaceuticals, Inc. (U.S.), and LEO Pharma A/S (Denmark), to name a few.
- In March 2017, U.S. FDA approved Regeneron/Sanofi’s anti-Interleukin-4R-alpha mAb Dupixent (Dupilumab) used in the treatment of atopic dermatitis
- In February 2016, Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. announced that they entered into a licensing agreement. The agreement provides Medimetriks, with development, marketing and manufacturing rights to OPA-15406 in the United States
- The report provides granular level information about the market size, regional market share and forecast from 2020–2026
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario